IDH1 and acute myeloid leukemia: For instance, HDACi Panobinostat treatment of a mouse model of AML bearing the AML1/ETO fusion triggered terminal myeloid differentiation with a remarkable anti-leukemic response19, and treatment with small-molecule inhibitors against IDH1/2 also induced myeloid differentiation in AML models with mutant IDH1/220,21.